QIAGEN QIAstat-Dx is expanding bloodstream infection testing capabilities across Europe. QIAGEN N.V. introduced the QIAstat-Dx BCID GN Plus AMR Panel, which has been certified under
The new panel strengthens the QIAstat-Dx platform with advanced molecular diagnostics. It detects 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers. Additionally, it delivers results from positive blood cultures in about one hour.
The QIAstat-Dx BCID GN Plus AMR Panel joins the previously launched QIAstat-Dx BCID GPF Plus AMR Panel. Together, these solutions provide broader bloodstream infection testing coverage. They identify gram-positive bacteria, gram-negative bacteria, fungi, and important AMR markers.
“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship, and effective infection control.”
Expanding Bloodstream Infection Diagnostics with Faster AMR Detection
Moreover, the combined panels detect 33 pathogen targets and 28 antimicrobial resistance markers. Therefore, healthcare teams can receive faster insights for treatment decisions and infection control strategies. Bloodstream infections require rapid identification and effective treatment. Gram-negative pathogens remain among the leading causes of these infections. Furthermore, antimicrobial resistance continues to create major healthcare challenges worldwide.
Delayed detection of resistant bacteria often means that treatment will be delayed. Hence, the risks of adverse outcomes are increased. The QIAstat-Dx BCID GN Plus AMR Panel can help to solve these problems by providing practical molecular information.
The panel focuses on key beta-lactam resistance mechanisms. These include resistance linked to extended-spectrum beta-lactamase (ESBL) and carbapenemase-producing organisms. Consequently, laboratories can support optimized therapies and stronger infection control programs.
Moreover, the QIAstat-Dx BCID GN Plus AMR Panel is CE-IVDR certified. The same is available in relevant European markets. Approval process through the FDA in the United States is in progress. Further expansion of the QIAstat-Dx menu to various infectious disease categories is being conducted by QIAGEN. Respiratory infections, gastrointestinal infections, and CNS infections are some of them.
The QIAstat-Dx technology offers rapid cartridge-based molecular diagnostics. The technology is designed to integrate sample preparation, testing, and result interpretation into a single process. Having deployed over 5,200 instruments globally, the QIAstat-Dx platform remains a reliable diagnostic solution in over 100 countries.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
